ASCO 2016: Continued Focus on Immunotherapy in Lung Cancer

Published on

Topics include: Treatments

What is the latest news on lung cancer immunotherapies?  On location at ASCO 2016, Dr. Charu Aggarwal of the University of Pennsylvania Hospital gives an update.  Dr. Aggarwal gives a brief glimpse at the results of combination immunotherapy data, including crizotinib (Xalkori) and alectinib (Alecensa). 

View more programs featuring and

Produced in association with

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. 

Dr. Aggarwal:

I think there is also a big focus on immunotherapy, and that continues, as we have seen, over the past several years since the first immunotherapy drugs came around.  And I think what's exciting this year is that we're seeing combination immunotherapy data, and we're seeing results in not only later lines of therapy, you know, but also in front?line, and for treatment of patients who have not received treatment before 

And, you know, I think another aspect of targeted therapy that's important this year is, you know, there are so many new drugs for ALK mutant lung cancer patients now, and how do we really decide which one to use first-line, second-line, third-line.  There is data on erlotinib (Tarveva) compared to crizotinib (Xalkori) in the first?line setting, which is going to be rewarded at this meeting, which is very exciting.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. 

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on June 21, 2016